Hemostemix Inc.
HEM
Rank in Stocks
#32553
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Share Price
$0.04403621
Last synced: 2026-10-16
Market Cap
$9.31M
Change (1 day)
0.00%
Change (1 year)
-40.80%
Country
CA
Trade Hemostemix Inc. (HEM)
Category
Healthcare
Market Capitalization of Hemostemix Inc.(HEM)
Market Cap: $9.31M
As of October 2026 Hemostemix Inc. has a market cap of $9.31M. This makes Hemostemix Inc. the world's 32553rd most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Hemostemix Inc. from 2005 to 2026
HEM compared with Top 5 Most Popular stocks
